Apollo Biowellness, Inc., Corporate Update

Rhea-AI Summary

Apollo Biowellness (OTC Pink: KOAN) announced several major business developments and strategic initiatives. The company has received approval to file on OTCIQ and is in final negotiations with a NASDAQ-listed Israeli Bio-Tech and Biologics manufacturer for co-developing Ceilo Skin Care, a shelf-stable biologic cosmetic planned for Q4 2025 launch.

Additionally, KOAN is negotiating a potential business combination with a large aesthetic company specializing in Laser Energy Devices. The company also plans to launch a first-of-its-kind Pet and Veterinarian Biologic product in Q3 2025, featuring exosomes and placental products for treating various pet health conditions.

The company is working with debt holders to restructure, refinance, or convert positions to preferred equity to support its 12-month growth strategy.

Positive

• Secured approval to file on OTCIQ, enhancing market presence
• Strategic partnership negotiation with NASDAQ-listed Israeli biotech firm for Q4 2025 product launch
• Potential merger/business combination with large aesthetic device company
• Planned launch of innovative pet biologics product in Q3 2025
• Active debt restructuring efforts to support growth plans

Negative

• Significant debt position requiring restructuring or refinancing
• Multiple projects in negotiation phase with no finalized agreements
• Dependent on successful debt holder negotiations for growth plans

North Bergen, New Jersey--(Newsfile Corp. - August 18, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company"), is pleased to announce that it has been approved to file on OTCIQ. The Company is also providing the following updates.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/262722_969ba78954e00ae4_001full.jpg

The Company is in final negotiations with an Israeli based Bio-Tech and Biologics manufacturer, listed on NASDAQ, for the co-development of our shelf-stable biologic cosmetic, which is planned to be launched in the 4^th Quarter of 2025. The shelf-stable biologic cosmetic is to be known as Ceilo Skin Care, and will be sold through retail, direct-to-consumer and e-commerce platforms.

In addition, the Company is in negotiations with a large aesthetic company in the business of Laser Energy Devices and products that are marketed and sold to Plastic Surgeons, Dermatologists, Med Spa's and Aesthetic Clinicians. The negotiations are for the purpose of a business combination or potential merger to create a combination therapy company, where we will sell Biologics and Aesthetic devices hand-in-glove.

Also, before the end of the 3^rd Quarter of 2025, Apollo will launch the first of its kind Pet and Veterinarian Biologic, using exosomes and placental products, for Pets, via a Doctor branded product, sold exclusively through licensed Veterinarians, Clinicians and Pet Professionals. This product will be using 100% natural biologic products to treat pets for arthritis issues, joint issues, inflammation issues and skin issues. Our product will include topical and injectable therapeutics.

The Company will be releasing more details as they become relevant regarding these events in the days and weeks to come, and in parallel with these actions, the Company is also working with its Debt Holders and Convertible Note Holders to either restructure, refinance or convert the majority of the positions to a preferred class of equity. This is line with the plan of management to coordinate financing for the Company to allow the plans for growth for the next 12 months.

James W. Zimbler, President and CEO, stated, "I am very eager for the new start for our biologic products company, along with the potential for new areas of activity. I anticipate an exciting next 12 months for the Company."

The Company uses the following handle on X at @ApolloBioKOAN to communicate with its shareholders

About Apollo Biowellness, Inc.

Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.

Before using any of our products, you should always consult with your veterinarian and/or family doctor.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com
https://evobiologics.com/
631-806-1420

X at @ApolloBioKOAN

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262722

FAQ

What are the main developments announced in Apollo Biowellness (KOAN) corporate update?

Apollo Biowellness announced three major developments: approval to file on OTCIQ, negotiations with a NASDAQ-listed Israeli biotech firm for cosmetic product development, and plans to launch a pet biologics product in Q3 2025.

When will Apollo Biowellness (KOAN) launch its Ceilo Skin Care product?

Apollo Biowellness plans to launch Ceilo Skin Care, its shelf-stable biologic cosmetic product, in the 4th Quarter of 2025.

What is Apollo Biowellness's (KOAN) strategy for addressing its debt?

The company is working with debt holders to either restructure, refinance, or convert the majority of positions to a preferred class of equity to support its 12-month growth plan.

What type of pet health products is Apollo Biowellness (KOAN) developing?

Apollo is developing biologic products using exosomes and placental products for pets, targeting arthritis, joint issues, inflammation, and skin conditions, available through licensed veterinarians.

What potential merger is Apollo Biowellness (KOAN) exploring?

Apollo is in negotiations for a potential merger with a large aesthetic company specializing in Laser Energy Devices to create a combination therapy company offering both biologics and aesthetic devices.